CJC-1295 DAC 10mg is a research peptide vial size. Learn how it differs from 5mg, typical dosing protocols, storage, and safety considerations.
CJC-1295 DAC 10mg is a 10-milligram vial of a long-acting growth hormone-releasing hormone (GHRH) analog used in laboratory research. The 10mg size is a bulk quantity that scientists reconstitute and aliquot for in vitro or animal studies. CJC-1295 DAC is not FDA-approved for human use, and it is sold strictly as a research chemical.
What Is CJC-1295 DAC 10mg?
CJC-1295 DAC is a modified peptide that includes a Drug Affinity Complex (DAC) designed to extend its half-life. The DAC binds to albumin in the bloodstream, which slows clearance and allows for less frequent administration in research models. A 10mg vial provides enough material for multiple experiments when reconstituted properly.
The 10mg label refers only to the quantity of lyophilized powder in the vial. It does not change the peptide's mechanism of action. Researchers who need smaller aliquots often choose a 5mg format instead. For example, a lab that runs only a few assays per month may prefer a cjc 1295 dac 5mg vial to reduce waste after reconstitution.
CJC-1295 DAC vs No DAC: Key Differences
The main difference between CJC-1295 DAC and CJC-1295 No DAC (also called Mod GRF 1-29) is the half-life. The DAC version lasts much longer in circulation. When researchers compare cjc-1295 dac vs no dac, they are usually weighing convenience against control.
| Feature | CJC-1295 DAC | CJC-1295 No DAC |
|---|---|---|
| Half-life | Approximately 6–8 days in human trials | Approximately 30 minutes |
| Albumin binding | Yes, via DAC | No |
| Injection frequency in research | Once weekly or less | Multiple times daily |
| Pulsatility | Blunted, continuous exposure | Preserves natural pulses |
| Common research focus | Long-term GH/IGF-1 elevation | Pulsatile GH release studies |
CJC-1295 DAC is not a replacement for CJC-1295 No DAC in every experimental design. The long half-life can create steady hormone levels, while the no-DAC version mimics the body's pulsatile release more closely. Neither peptide is approved for human use.
Typical Research Dosing and Protocol Considerations
There is no standard human dose for CJC-1295 DAC because it is not an approved drug. Published pharmacokinetic studies in healthy adults used single doses ranging from 30 to 60 mcg/kg, but those were controlled trials, not clinical recommendations. Any cjc-1295 with dac dosage found online should be treated as unverified unless it cites peer-reviewed animal or in vitro data.
Researchers working with cell cultures often use concentrations between 10 nM and 1 µM. Animal studies may use 1–2 mg per week in divided doses, depending on the model. By contrast, cjc-1295 no dac dosage protocols typically require daily or twice-daily injections because of the short half-life.
Always follow your institution's IACUC or IRB guidelines. Document reconstitution volume, storage temperature, and administration route for reproducibility. Do not extrapolate animal doses to humans.
Blends and Related Research Peptides
CJC-1295 is sometimes studied alongside ipamorelin, a selective growth hormone secretagogue. A 10mg blend may contain both peptides in a fixed ratio, which changes the dosing math. For a combo product, you cannot assume the 10mg refers to CJC-1295 alone. The label should state the exact amount of each peptide.
Researchers comparing a CJC-1295 and ipamorelin blend with separate vials often find that blends offer convenience but less flexibility. You cannot adjust one peptide without changing the other. If your protocol requires precise titration, separate vials are usually better.
Storage, Handling, and Sourcing
Lyophilized CJC-1295 DAC 10mg should be stored at -20°C or lower, protected from light. After reconstitution with bacteriostatic water, keep the vial at 2–8°C and use it within a few weeks. Avoid repeated freeze-thaw cycles, which can degrade the peptide.
When you see cjc 1295 dac for sale listings, check for a third-party certificate of analysis (COA). A COA should report purity by HPLC and mass by MS. Vials without a COA carry unknown risks, including incorrect peptide identity or bacterial contamination.
Legal status varies by country. In the United States, CJC-1295 DAC is not approved by the FDA for any human indication. It is sold as a research chemical only, and importing it for personal use may violate federal law.
Safety and Side Effects in Research
Clinical trials of CJC-1295 DAC reported injection-site reactions, headache, flushing, and transient changes in heart rate. These effects were generally mild but occurred in a research setting with medical supervision. Long-term safety data in humans are lacking.
CJC-1295 DAC can affect growth hormone and IGF-1 levels. Elevated IGF-1 is associated with several health risks, including edema and joint pain. Anyone considering non-research use should consult a licensed healthcare professional. Self-administration of research peptides is not advised.
Frequently Asked Questions
What is CJC-1295 DAC 10mg?
CJC-1295 DAC 10mg is a 10-milligram vial of a long-acting GHRH analog sold for laboratory research. It is not an FDA-approved drug, and it is not intended for human consumption.
How do you reconstitute a 10mg vial of CJC-1295 DAC?
Add bacteriostatic water slowly to the lyophilized powder, aiming the stream at the vial wall instead of the powder. A common ratio is 1 mL per 10mg, but the exact volume depends on your desired concentration. Swirl gently; do not shake.
Is CJC-1295 DAC legal to buy in the United States?
CJC-1295 DAC is not FDA-approved for human use. It is sold as a research chemical, and purchasing it for personal consumption may violate federal law. Always check local regulations and institutional policies.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.